Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galinpepimut-S in AML/ALL Patients in Complete Remission
NCT01266083Phase 2Completed
- Sponsor
- SELLAS Life Sciences Group, Inc.
- Start
- Jan 2011
- Primary completion
- Sep 2016
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of galinpepimut-s in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), sponsored by SELLAS Life Sciences Group, Inc.. Started Jan 2011; status: completed.
02
Drugs
galinpepimut-s
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01266083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01266083.